Dong-A Pharmaceutical Co., a subsidiary of Dong-A Socio Holdings, said on the 20th that its hyperpigmentation treatment Melatoning Cream surpassed a cumulative 3 million units sold five years after its launch.
Melatoning Cream is a hyperpigmentation treatment containing 2% hydroquinone, launched in 2021. Hydroquinone inhibits tyrosinase, an enzyme that promotes melanin production, to prevent excessive melanin formation, and acts on melanosomes within melanocytes to bleach already deposited pigment, helping improve hyperpigmentation such as melasma and freckles.
Dong-A Pharmaceutical Co. enhanced ease of use by adopting a tube-type package, and recently released a 50g large-capacity product for use not only on the face but also on body areas. Along with this, it also offers Melanosa Cream with 4% hydroquinone, operating a tailored product lineup according to the degree of hyperpigmentation.
According to IQVIA, Melatoning Cream has maintained market leadership with a share of more than 70% in the hydroquinone segment since 2023. Last year, it surpassed 1.3 million units in annual sales, establishing itself as a leading hyperpigmentation treatment.
Dong-A Pharmaceutical Co. recently selected actor Jeon Ji-hyun as its advertising model and is strengthening marketing activities. The advertisement emphasized the over-the-counter hyperpigmentation treatment and the pharmacy sales channel with the message, "Melatoning Cream is only at pharmacies!"
An official at Dong-A Pharmaceutical Co. said, "We were able to surpass a cumulative 3 million units sold in five years thanks to consumer trust," and added, "We will continue to strengthen product competitiveness to help consumers seeking hyperpigmentation treatment."